about
(18)F-fluoride positron emission tomography/computed tomography and bone scintigraphy for diagnosis of bone metastases in newly diagnosed, high-risk prostate cancer patients: study protocol for a multicentre, diagnostic test accuracy studyThree-minute SPECT/CT is sufficient for the assessment of bone metastasis as add-on to planar bone scintigraphy: prospective head-to-head comparison to 11-min SPECT/CT.Treatment with bone-seeking radionuclides for painful bone metastases in patients with lung cancer: a systematic review.Staging practice for prostate cancer varies and is not in line with clinical guidelines.68Ga-PSMA PET/CT for the detection of bone metastasis in recurrent prostate cancer and a PSA level <2 ng/ml: Two case reports and a literature review.(68)Ga-PSMA-11 PET/CT interobserver agreement for prostate cancer assessments: an international multicenter prospective study.Safety and tolerability of regadenoson for myocardial perfusion imaging - first Danish experience.Prospective evaluation of computer-assisted analysis of skeletal lesions for the staging of prostate cancerComputer-assisted interpretation of planar whole-body bone scintigraphy in patients with newly diagnosed prostate cancer.Prospective multicenter study of bone scintigraphy in consecutive patients with newly diagnosed prostate cancer.Diagnostic test accuracy study of 18F-sodium fluoride PET/CT, 99mTc-labelled diphosphonate SPECT/CT, and planar bone scintigraphy for diagnosis of bone metastases in newly diagnosed, high-risk prostate cancer.Avid 18F-FDG Uptake in Idiopathic Tumoral Calcinosis Mimicking Lymph Node Metastasis.(68) Ga-PSMA PET/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature.Comparison of two methods based on photoplethysmography for the diagnosis of peripheral arterial disease.Validation of contemporary guidelines for bone scintigraphy in prostate cancer staging: A prospective study in patients undergoing radical prostatectomy.Bone Scan Index Is an Independent Predictor of Time to Castration-resistant Prostate Cancer in Newly Diagnosed Prostate Cancer: A Prospective Study.WITHDRAWN: Author Reply to the Editorial Comment on: Zacho HD, Gade M, Mortensen JC, Bertelsen H, Boldsen SK, Petersen LJ. Bone Scan Index Is an Independent Predictor for Time to Castration Resistant Prostate Cancer in Newly Diagnosed Prostate CanceA Comprehensive Safety Evaluation of 68Ga-Labeled Ligand Prostate-Specific Membrane Antigen 11 PET/CT in Prostate Cancer: The Results of 2 Prospective, Multicenter Trials.68Ga-PSMA PET/CT Uptake in Intramuscular Myxoma Imitates Prostate Cancer Metastasis.Accuracy of 18F-FDG PET-CT in triaging lung cancer patients with suspected brain metastases for MRI.Observer agreement of treatment responses on planar bone scintigraphy in prostate cancer patients: importance of the lesion assessment method.Incidental Detection of Thyroid Metastases From Renal Cell Carcinoma Using 68Ga-PSMA PET/CT to Assess Prostate Cancer Recurrence.Unexplained Bone Pain Is an Independent Risk Factor for Bone Metastases in Newly Diagnosed Prostate Cancer: A Prospective Study.Observer agreement and accuracy in the evaluation of bone scans in newly diagnosed prostate cancer.Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging GroupReply by the AuthorsGallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography for staging of high-risk prostate cancerProspective comparison of 68Ga-PSMA PET/CT, 18F-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancerAdded value of 68Ga-PSMA PET/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer and a previous 99mTc bone scintigraphyGiant Hepatic Artery AneurysmAssessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial
P50
Q35890956-3C62E0B1-DCD1-4BF4-A57B-79524B02A9F1Q37562219-DCE2273E-C89B-48D5-926A-DF53D2C5491BQ38714051-341F0767-F70E-4862-B681-A7B6C282887BQ39136797-CA85EB51-C2B6-481F-B304-A9951AAB45D1Q39419798-121CB317-75B4-44F5-B8EE-6A0C7A92ACC4Q40243006-1F3B5E55-F5D2-4731-90D7-6F3B3AA8A47CQ40865264-05705031-4F72-4F5E-AF8E-2B5F5A97B6DEQ40977755-8591817E-1801-4595-9FB8-E9DE3F087DD2Q41254354-A343CB9F-36D3-4C05-B8D6-AF18AF68C82FQ43726876-0233DD00-50FB-41D5-9574-7647DD77CB90Q47136477-3CE0A377-9161-4238-AA9F-CADF0294A41EQ47183023-762B6B0E-FB88-43E0-B004-9F18A111D4D0Q47693515-810C8DC3-DB49-4A76-975E-7A91831D0E94Q48171106-9E992D27-7B97-439B-8D0D-8EB32495E6B8Q48952907-D337CE82-DF87-42BC-AFD8-30FDDA92B1E7Q50515656-C738E9CA-1C3C-4001-B0D4-E497D91A5FC5Q50517003-B034D79E-2785-4113-9D9D-2027B44E0125Q50665050-A297E145-2BBD-403D-A04E-DF829787EF01Q51075546-E93A517B-F174-462F-A413-75FAEB1FC7E6Q52150653-E922CFA2-BE4C-4041-88BF-BC836282CC87Q52925306-9BB20A16-E11D-4FEE-9C4C-BF13EF27543CQ52935180-7054B464-1F1A-43BD-AF66-C73BAE30583EQ52966422-E89EEF62-C17F-49FE-843F-09F2825F7906Q53164777-393272A9-89A8-4FFC-A2BA-9D8273910ABFQ57299101-F484D3E6-7F1A-45D1-9ACB-03294A7CAA0AQ60681551-A31A71C7-EE67-4C3A-A0ED-A2A19D429658Q88615938-8776726D-0167-48BE-886B-2E187985E8C7Q89017227-18A2A556-E464-40E8-956F-DA09529A5403Q91747723-F4EC926A-A514-41FC-8FF7-CA982EE71718Q91998933-97EBF9A1-1877-4CF8-8063-769C8FEEAF74Q92671536-C5502AE8-E70A-487A-AC1C-B31EDCAA59F1
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Helle D Zacho
@ast
Helle D Zacho
@en
Helle D Zacho
@es
Helle D Zacho
@nl
Helle D Zacho
@sl
type
label
Helle D Zacho
@ast
Helle D Zacho
@en
Helle D Zacho
@es
Helle D Zacho
@nl
Helle D Zacho
@sl
prefLabel
Helle D Zacho
@ast
Helle D Zacho
@en
Helle D Zacho
@es
Helle D Zacho
@nl
Helle D Zacho
@sl
P106
P31
P496
0000-0001-9089-288X